Gregory Riggins
Affiliations: | Johns Hopkins University, Baltimore, MD |
Area:
Oncology, Pathology, Neuroscience BiologyGoogle:
"Gregory Riggins"Mean distance: 53433
Parents
Sign in to add mentor| Stephen T. Warren | grad student | 1989-1994 | Emory University School of Medicine |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yamashita AS, da Costa Rosa M, Stumpo V, et al. (2021) The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling. Neuro-Oncology Advances. 3: vdaa149 |
| Yamashita AS, da Costa Rosa M, Borodovsky A, et al. (2018) Demethylation and epigenetic modification with 5-Azacytidine reduces IDH1 mutant glioma growth in combination with Temozolomide. Neuro-Oncology |
| Danussi C, Bose P, Parthasarathy PT, et al. (2018) Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nature Communications. 9: 1057 |
| Bautista W, Abu-Asab M, Amable L, et al. (2018) 19 Autophagy related metals in IDH1 mutant glioma: Chloroquine and TMZ as a potential novel strategy to treat IDH1 mt gliomas Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques. 45: S3-S4 |
| Borodovsky A, Meeker AK, Kirkness EF, et al. (2015) A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. Journal of Neuro-Oncology. 121: 479-87 |
| Borodovsky A, Riggins G. (2014) Et-08Demethylating Therapy Induces Differentation And Therapeutic Response In Idh1 Mutant Malignant Gliomas. Neuro-Oncology. 16 |
| Bai R, Staedtke V, Rudin C, et al. (2014) ET-04 * MEBENDAZOLE IS EFFICACIOUS IN DIVERSE MEDULLOBLASTOMA TUMOR MODELS AND INHIBITS TUMOR ANGIOGENESIS Neuro-Oncology. 16: v79-v79 |
| Turcan S, Fabius AW, Borodovsky A, et al. (2013) Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. 4: 1729-36 |
| Borodovsky A, Salmasi V, Turcan S, et al. (2013) 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 4: 1737-47 |
| Killela PJ, Reitman ZJ, Jiao Y, et al. (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 110: 6021-6 |